JP2018521674A - プロピオネート異化を伴う障害を治療するために操作された細菌 - Google Patents

プロピオネート異化を伴う障害を治療するために操作された細菌 Download PDF

Info

Publication number
JP2018521674A
JP2018521674A JP2018504991A JP2018504991A JP2018521674A JP 2018521674 A JP2018521674 A JP 2018521674A JP 2018504991 A JP2018504991 A JP 2018504991A JP 2018504991 A JP2018504991 A JP 2018504991A JP 2018521674 A JP2018521674 A JP 2018521674A
Authority
JP
Japan
Prior art keywords
propionate
gene
encoding
bacterium
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018504991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521674A5 (enExample
Inventor
ファルブ ディーン
ファルブ ディーン
ミラー ポール
ミラー ポール
タッカー アレックス
タッカー アレックス
コツラ ジョナサン
コツラ ジョナサン
イザベラ ビンセント
イザベラ ビンセント
ミレー イブ
ミレー イブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synlogic Inc
Original Assignee
Synlogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/en
Priority claimed from PCT/US2016/037098 external-priority patent/WO2016201380A1/en
Application filed by Synlogic Inc filed Critical Synlogic Inc
Publication of JP2018521674A publication Critical patent/JP2018521674A/ja
Publication of JP2018521674A5 publication Critical patent/JP2018521674A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018504991A 2015-07-31 2016-07-29 プロピオネート異化を伴う障害を治療するために操作された細菌 Pending JP2018521674A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562199445P 2015-07-31 2015-07-31
US62/199,445 2015-07-31
US201662336338P 2016-05-13 2016-05-13
US62/336,338 2016-05-13
USPCT/US2016/032565 2016-05-13
PCT/US2016/032565 WO2016183532A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to treat a disease or disorder
US201662341320P 2016-05-25 2016-05-25
US62/341,320 2016-05-25
USPCT/US2016/037098 2016-06-10
PCT/US2016/037098 WO2016201380A1 (en) 2015-06-10 2016-06-10 Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
PCT/US2016/044922 WO2017023818A1 (en) 2015-07-31 2016-07-29 Bacteria engineered to treat disorders involving propionate catabolism

Publications (2)

Publication Number Publication Date
JP2018521674A true JP2018521674A (ja) 2018-08-09
JP2018521674A5 JP2018521674A5 (enExample) 2019-09-05

Family

ID=57944027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504991A Pending JP2018521674A (ja) 2015-07-31 2016-07-29 プロピオネート異化を伴う障害を治療するために操作された細菌

Country Status (5)

Country Link
EP (1) EP3328988A1 (enExample)
JP (1) JP2018521674A (enExample)
AU (1) AU2016303662A1 (enExample)
CA (1) CA2996535A1 (enExample)
WO (1) WO2017023818A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021112055A1 (ja) * 2019-12-02 2021-06-10 アステラス製薬株式会社 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞
JP2023511305A (ja) * 2020-01-17 2023-03-17 ウニベルシテ カソリーク デ ルーベン 変化したエンベロープ完全性を有する遺伝子組換え細菌およびその使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3720458A4 (en) * 2017-12-05 2021-12-08 BioPlx, Inc. METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION
AU2020288624B2 (en) 2019-06-04 2025-09-25 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN112143689B (zh) * 2019-06-28 2023-01-03 中国科学院微生物研究所 重组恶臭假单胞菌株的构建及其在转化苏氨酸合成丙酸中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525266A (ja) * 2011-08-26 2014-09-29 マイクロバイオータ ダイアグノスティクス， エルエルシー 心欠陥を診断および治療する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1135461A4 (en) 1998-12-02 2003-03-26 Univ Boston GEN NETWORKS FOR CONTROLLING GENE EXPRESSION
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20150246085A1 (en) * 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
WO2014138324A1 (en) 2013-03-07 2014-09-12 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525266A (ja) * 2011-08-26 2014-09-29 マイクロバイオータ ダイアグノスティクス， エルエルシー 心欠陥を診断および治療する方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GARRITY J.. ET AL.: "N-lysine propionylation controls the activity of propionyl-CoA synthetase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282(41), JPN6020020779, 2007, pages 30239 - 30245, ISSN: 0004649286 *
HORNG YT. ET AL.: "Biosynthesis of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) with co-expressed propionate permease (", BIOCHEMICAL ENGINEERING JOURNAL, vol. 78(15), JPN6020020780, 2013, pages 73 - 79, ISSN: 0004649287 *
ILANA ALDOR; ET AL: "METABOLIC ENGINEERING OF POLY(3‐HYDROXYBUTYRATE‐CO‐3‐HYDROXYVALERATE) COMPOSITION IN 以下備考", BIOTECHNOLOGY AND BIOENGINEERING, vol. VOLUME76, ISSUE2, JPN5018004812, September 2001 (2001-09-01), US, pages 108 - 114, ISSN: 0004511836 *
MURLI S. ET AL.: "Metabolic engineering of Escherichia coli for improved 6-deoxyerythronolide B production", JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, vol. 30(8), JPN6020020777, 2003, pages 500 - 509, ISSN: 0004649284 *
WONG MS; ET AL: "ENGINEERING POLY(3-HYDROXYBUTYRATE-CO-3-HYDROXYVALERATE) COPOLYMER COMPOSITION IN E. COLI", BIOTECHNOLOGY AND BIOENGINEERING, vol. V99 N4, JPN5018004811, 2008, US, pages 919 - 928, ISSN: 0004511837 *
生化学, 2015.06.25, VOL.87, NO. 3, PP. 286-291, JPN6020020778, ISSN: 0004649285 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021112055A1 (ja) * 2019-12-02 2021-06-10 アステラス製薬株式会社 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞
JPWO2021112055A1 (enExample) * 2019-12-02 2021-06-10
US11672851B2 (en) 2019-12-02 2023-06-13 Riken NY-ESO-1-containing artificial adjuvant vector cell for use in treatment of cancer
JP7646213B2 (ja) 2019-12-02 2025-03-17 国立研究開発法人理化学研究所 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞
JP2023511305A (ja) * 2020-01-17 2023-03-17 ウニベルシテ カソリーク デ ルーベン 変化したエンベロープ完全性を有する遺伝子組換え細菌およびその使用

Also Published As

Publication number Publication date
WO2017023818A1 (en) 2017-02-09
AU2016303662A1 (en) 2018-02-22
EP3328988A1 (en) 2018-06-06
CA2996535A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
US12409195B2 (en) Bacteria engineered to reduce hyperphenylalaninemia
US20220233609A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
EP3307870B1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
US9688967B2 (en) Bacteria engineered to treat diseases associated with hyperammonemia
US10273489B2 (en) Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
JP6817966B2 (ja) 高アンモニア血症に関連する疾患を治療するために操作された細菌
US20170216370A1 (en) Bacteria engineered to treat disorders involving propionate catabolism
WO2016210373A2 (en) Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
US20230092431A1 (en) Bacteria engineered to treat disorders in which oxalate is detrimental
WO2017123592A1 (en) Bacteria engineered to treat disorders associated with bile salts
WO2017075485A1 (en) Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
US20230090705A1 (en) Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
JP2018521674A (ja) プロピオネート異化を伴う障害を治療するために操作された細菌
US20220168362A1 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
US20230174926A1 (en) Bacteria engineered to treat disorders involving the catabolism of leucine

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20180329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211130